THE INFLUENCE OF HYDROGEN SULFIDE DEFICIENCY ON PATHOGENETIC MECHANISMS FOR PROGRESSION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AGAINST THE BACKGROUND OF OBESITY
DOI:
https://doi.org/10.11603/1811-2471.2019.v0.i1.10067Keywords:
chronic obstructive pulmonary disease, nonalcoholic steatohepatitis, obesityAbstract
Comprehensive studies of homeostasis of hydrogen sulfide (Н2S) may open new mechanisms of complications of chronic obstructive pulmonary disease (COPD) and nonalcoholic steatohepatitis (NASH).
The aim of the study – to establish the role of Н2S in the mechanisms of progression of COPD and NASH on the background of obesity.
Material and Methods. 100 patients with COPD were examined, including 49 with NASH and obesity of the 1st degree: group 1 – 28 patients with COPD (2B GOLD). Group 2 – 23 patients with COPD (3C, D). Group 3 – 25 patients with COPD (2B) with NASH. Group 4 – 24 patients with COPD (3C, D) and NASH. Control group – 20 healthy persons (HP).
Results. The content of Н2S in blood in HP was (75.3±3.2) μmol/l. In patients of all groups, the content of Н2S in the blood was reduced: in patients of group 1 and 2 – in 1.3 and 1.7 times (p<0.05), in patients of group 3 and 4 – in 2.2 and 2.9 times (p<0.05) in comparison with HP (p<0.05). With the increase of COPD stage and in case of NASH comorbidity the content of Н2S probably decreased. The following correlation relationships have been set: Н2S content and the hepatocyte cytolysis activity (ALT: r=-0.63-0.66, p<0.05), bronchoconstriction (FEV1: r=0.69, p<0.05), hyperlipidemia (r=-0,52-0,61, p<0,05), hyperproduction of connective tissue components (protein-bound oxyproline, glycosaminoglycans, fibronectin, hexosamines, sialic acids), indicating organ fibrosis (r = -0.65-0.71, p<0.05), proteolysis (r = -0.48-0.56, p<0.05), endothelial dysfunction (nitrogen monoxide, homocysteine (r=-0.55-0.69, p<0.05)) indicate the role of the Н2S deficiency in the mechanisms of progression of comorbid diseases.
Conclusions. The deficiency of H2S in the blood probably affects the mechanisms of progression of COPD and NASH on the background of obesity based on the research of content of protein and carbohydrate-protein components of the extracellular matrix and proteinase-inhibitory system, lipid profile, endothelial functional status.
References
Babak, O.Ya., & Kolesnikova, O.V. (2008). Stan syrovatkovykh markeriv fibrozu pechinky pry nealkoholnii zhyrovii khvorobi pechinky [Status of serum liver fibrosis markers in non-alcoholic fatty liver disease]. Suchasna hastroenterolohiia – Modern Gastroenterology, 3 (41), 9-13 [in Ukrainian].
Hryniuk, O.Ye., Khukhlina, O.S., Antoniv, A.A., & Mandryk, O.Ye. (2018). Nealkoholna zhyrova khvoroba pechinky, ozhyrinnia ta khronichne obstruktyvne zakhvoriuvannia lehen: chynnyky ryzyku ta mekhanizmy vzaiemoobtiazhennia ta prohresuvannia [Non-alcoholic fatty liver disease, obesity and chronic obstructive pulmonary disease: risk factors and mechanisms of interweaving and progression]. Nealkoholna zhyrova khvoroba pechinky ta komorbidni stany: osoblyvosti patohenezu, kliniky, diahnostyky, likuvannia: kol. monoh. – Non-alcoholic fatty liver disease and comorbid conditions: peculiarities of pathogenesis, clinics, diagnostics, treatment. Chernivtsi [in Ukrainian].
Ratziu, V., Bellentani, S., & Cortez–Pinto, H. (2010). A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of Hepatology, 53 (2), 372-384.
Fang, L.P., Lin, Q., Tang, C.S, & Liu, X.M. (2009). Hydrogen sulfide suppresses migration, proliferation and myofibroblast transdifferentiation of human lung fibroblasts. Pulmonary Pharmacology and Therapeutics, 22 (6), 554-561.
Guo, C., Liang, F., Shah Masood, W., & Yan, X. (2014). Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 s-sulfhydration, MAPK dependent anti-apoptosis and NF-κB dependent anti-inflammation pathway. European Journal of Pharmacology, 725 (1), 70-78.
Fang, L., Li, H., & Tang, C. (2009). Hydrogen sulfide attenuates the pathogenesis of pulmonary fibrosis induced by bleomycin in rats. Physiol. Pharmacol., 87 (7), 531-538. doi: 10.1139/y09-039.
Fan, H.N., Wang, H.J., & Yang-Dan, C.R. (2013). Protective effects of hydrogen sulfide on oxidative stress and fibrosis in hepatic stellate cells. Mol. Med. Rep. 7 (1), 247-253.
Chen, Y.H., Yao, W.Z., & Gao, J.Z. (2009). Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections. Respirology, 14 (5), 746-752.
Wortley, K.E., del Rincon, J.P., & Murray, J.D. (2005). Absence of ghrelin protects against early–onset obesity. J. Clin. Invest., 115 (12), 3573-3578.
Adams, L.A., & Lindor, K.D. (2007). Nonalcoholic fatty liver disease. Ann. Epidemiol., 17 (11), 863-869.
Chalasani, N., Younossi, Z., & Lavine, J.E. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol., 107 (6), 811-826.
Khukhlina, O.S., Hryniuk, O.Y., & Kovalenko, S.V. (2018). Clinical and pathogenetic features of nonalcoholic steatohepatitis for comorbidity with bronchial asthma on the background of obesity. Wiadomości Lekarskie, LXXI, 376.
Ruffillo, G., Fassio, E., & Alvarez, E. (2011). Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J. Hepatol., 54 (1), 160-163.
Wong, V.W., Vergniol, J., & Wong, G.L. (2010). Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology, 51 (2), 454-462.
Hossain, N., Afendy A., & Stepanova, M. (2009). Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol., 7 (11), 1224-1229.
